

# Application of New Approach Methodologies to Chemical Assessment and Regulatory Decision-Making: The Importance of an International and Harmonized Effort

Maureen R. Gwinn PhD DABT ATS  
Office of Research and Development  
US Environmental Protection Agency  
March 25, 2021

SOT Workshop:  
Regulatory Learnings from the EU Flagship  
Non-animal Toxicology Project, EU-ToxRisk

*The views expressed in this presentation are those of the authors and do not necessarily reflect the views or policies of the U.S. EPA*

This space reserved  
for video image.



# Conflict of Interest Statement

*The author declares no conflict of interest.*

*The views expressed in this presentation are those of the author and do not necessarily reflect the views or policies of the U.S. EPA.*



This space reserved  
for video image.


# Outline

- New Approach Methods
- Increasing Translation
- Harmonization effort examples:
  - EUToxRisk
  - OECD Environmental Health and Safety Programme
  - Accelerating the Pace of Chemical Risk Assessment
- Benefits of International Collaboration
- Continued Goals
- Acknowledgements




This space reserved  
for video image.

# Definition(s) of New Approach Methods (NAMs)



- Commonly defined to include in silico approaches, in chemico and in vitro assays, as well as the inclusion of information from the exposure of chemicals in the context of hazard and exposure assessment.
- Defined in the EPA's TSCA Alternative Toxicity Strategy as:
  - a broadly descriptive reference to any technology, methodology, approach, or combination thereof that can be used to provide information on chemical hazard and risk assessment that avoids the use of intact animals.







[https://echa.europa.eu/documents/10162/22816069/scientific\\_ws\\_proceedings\\_en.pdf](https://echa.europa.eu/documents/10162/22816069/scientific_ws_proceedings_en.pdf)

<https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/alternative-test-methods-and-strategies-reduce>

This space reserved  
for video image.

# Examples of New Approach Methods

- In silico (e.g. QSAR and Read-across)
  - Estimate effects and doses
  - Consensus exposure modeling
- In vitro assays
  - Broad / screening (transcriptomics, cell painting)
  - Targeted (receptors, enzymes)
  - In vitro PODs, modes / mechanisms of action
- In vitro Toxicokinetics
  - Allow conversion of an in vitro POD to in vivo (IVIVE)
- High-throughput Exposure Measurements
  - To fill data gaps in monitoring data
- Computer models
  - Hazard models to integrate multiple in silico and in vitro data streams
  - Exposure models to increase information on different pathways of exposure



This space reserved  
for video image.

# What is needed for increased translation of NAMs for regulatory decisions?

- Common understanding of current state of the science of NAMs, including the application in a regulatory context.
- Increase understanding of realistic benchmarks for performance of NAMs in different regulatory contexts.
- Increase engagement and commitment to development and sharing of case studies of mutual interest.
- Increase collaboration to strategically address barriers and limitations of use of NAMs in a regulatory context.



This space reserved  
for video image.

# Benefits of Collaboration

- Maximizing shared resources
- Benefitting from shared lessons learned
- Filling data gaps of common concern
- Engaging broader range of stakeholders
- Increasing understanding of NAMs applications



This space reserved  
for video image.

# Example 1: EU-ToxRisk

- An Integrated European 'Flagship' Programme Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st century.
- Began in 2016 and funded from the European Union's Horizon2020 research and innovation program.
- Aim was to develop the tools and strategies that will enable reliable animal-free risk assessment of chemicals.
- Further aim to increase close interaction among researchers and regulators to significantly improve targeting regulatory needs, thereby enhancing the societal impact of the project.



This space reserved  
for video image.



# Example 1: EU-ToxRisk Lessons Learned


- Main areas already discussed today:
  - Importance of practical case studies
  - Need for data sharing framework and data integration across case studies
  - Establishing a good regulatory reporting practice for NAMs (e.g., NAM-enhanced read-across)
  - Need to share with the international community to promote sustainability of the approach



This space reserved  
for video image.

# Example 1: EU-ToxRisk Impact

- Utilization of international discussion platforms for promoting the implementation of NAMs, mostly focused on NAM-enhanced RAX via:
  - **F2F meetings**, harvesting the collective experience of those developing and applying RAX approaches with NAMs to coordinate the ongoing opportunities and challenges in assuring scientific confidence in their use;
  - **Publications**, internationally promoting the regulatory implementation of NAM-based RAX, i.e. the EU-ToxRisk CS reports published by the IATA Case Studies Project.



This space reserved  
for video image.

## Example 2: OECD ENVIRONMENT, HEALTH AND SAFETY (EHS) DIVISION

38 Member Countries, many partner countries and other stakeholders work together to develop and co-ordinate activities on chemical safety and biosafety on an international basis. One of the core aspects of the work relates to the Mutual Acceptance of Data.

The main objectives of EHS are to:

- Assist OECD Member countries' efforts to protect human health and the environment through improving chemical safety and biosafety;
- Make chemical control policies more transparent and efficient and save resources for government and industry; and
- Prevent unnecessary distortions in the trade of chemicals, chemical products and products of modern biotechnology.



<http://www.oecd.org/env/ehs/>

This space reserved  
for video image.

# Example 2: OECD Methodologies for Hazard Assessment



- Works with member countries and other stakeholders to cooperatively assess the hazard of chemicals
  - Tools and information are publicly available
  - Can be used for priority setting, risk assessment, and other activities
  - Improve and harmonize chemicals assessment methods using the most current science
  - Generate confidence and support for integrating novel tools and approaches into regulatory decision-making
- Types of Output:
  - Guidance Documents and case studies using novel methods for regulatory decision-making
  - Adverse Outcome Pathways Knowledge Base
  - QSAR Toolbox
  - Integrated approaches to testing and assessment (IATA)



<http://www.oecd.org/env/ehs/risk-assessment/>

This space reserved  
for video image.

# Example 2: OECD – Integrated Approaches to Testing and Assessment (IATA) Case Studies Project

- Objective:
  - Increase experience with the use of IATA by developing case studies, which constitute examples of predictions that are fit for regulatory use
  - Provide a scientific exchange on how novel methods are applied to assess the hazard of chemicals
  - Establish a common understanding and best practices for using novel methodologies in a regulatory context
- Deliverables:
  - Guidance documents on methodologies with associated case studies
  - Lessons learned/considerations from each IATA case study project cycle



<http://www.oecd.org/chemicalsafety/risk-assessment/iata-integrated-approaches-to-testing-and-assessment.htm>

This space reserved  
for video image.

# Example 2: OECD – IATA Case Studies Project

Review Year	Title	Endpoint	Status
2020	Case Study on the use of Integrated Approaches for Testing and Assessment for the Systemic Toxicity of Phenoxyethanol when included at 1% in a body lotion	Repeated toxicity	Under Review
2019	Case Study on the use of an Integrated Approach to Testing and Assessment (IATA) and New Approach Methods to inform a Theoretical Read-Across for Dermal Exposure to Propylparaben from Cosmetics	Reproductive toxicity	<a href="#">Published</a>
2019	Case Study on the use of Integrated Approaches for Testing and Assessment for Systemic Toxicity Arising from Cosmetic Exposure to Caffeine	Repeated dose toxicity	<a href="#">Published</a>
2019	Case Study on the Use of Integrated Approaches for Testing and Assessment for 90-Day Rat Oral Repeated-Dose Toxicity of Chlorobenzene-Related Chemicals	Repeated dose toxicity	<a href="#">Published</a>
2019	Case Study on the Use of Integrated Approaches for Testing and Assessment to Inform Read-across of p-Alkylphenols: Repeated-Dose Toxicity	Repeated dose toxicity	<a href="#">Published</a>
2019	Prediction of a 90 day repeated dose toxicity study (OECD 408) for 2-Ethylbutyric acid using a read-across approach from other branched carboxylic acids	Repeated dose toxicity	<a href="#">Published</a> <a href="#">Annex III</a>
2019	Read-across based filling of developmental and reproductive toxicity data gap for methyl hexanoic acid	Developmental toxicity	<a href="#">Published</a> <a href="#">Annex II</a> <a href="#">Annex III</a>
2019	Identification and characterisation of parkinsonian hazard liability of deguelin by an AOP-based testing and read across approach	Neurotoxicity	<a href="#">Published</a> <a href="#">Annex I</a>
2019	Mitochondrial Complex-III-mediated neurotoxicity of - Read-Across to other strobilurins	Neurotoxicity	<a href="#">Published</a> <a href="#">Annex I</a>
2018	Case Study on the use of Integrated Approaches for Testing and Assessment for Testicular Toxicity of Ethylene Glycol Methyl Ether (EGME)-Related Chemicals	Reproductive toxicity	<a href="#">Published</a>
2018	Case Study on the Use of an Integrated Approach to Testing and Assessment for Identifying Estrogen Receptor Active Chemicals	Endocrine disruption	<a href="#">Published</a>



This space reserved  
for video image.



# Example 3: Accelerating the Pace of Chemical Risk Assessment

An international governmental collaboration that brings together governmental entities engaged in development of new hazard, exposure, and risk assessment methods and approaches for their chemical evaluation activities.



**APCRA**  
ACCELERATING THE PACE OF  
CHEMICAL RISK ASSESSMENT

- To discuss progress and barriers in applying new tools to prioritization, screening, and quantitative risk assessment of differing levels of complexity.
- To discuss opportunities to increase collaboration through case studies in order to accelerate the pace of chemical risk assessment.

<https://www.epa.gov/chemical-research/accelerating-pace-chemical-risk-assessment-apcra>

This space reserved  
for video image.



APCRA  
Accelerating the Pace  
of Chemical Risk Assessment  
October 9-10, 2019



# Example 3: APCRA Intergovernmental Collaborative Case Studies

- Case studies developed address the following criteria:
  - Common issue for more than one regulatory partner (e.g., PFAS)
  - Active engagement for more than one regulatory partner
  - Supports clear regulatory context
- Case study topic areas
  - Application to Human Health and Ecological Risk Evaluation
  - Application to Chemical Categorization
  - Application to Exposure Evaluation



**APCRA**  
ACCELERATING THE PACE OF  
CHEMICAL RISK ASSESSMENT



This space reserved  
for video image.



# Example 3: APCRA Completed Case Studies



## Utility of *In Vitro* Bioactivity as a Lower Bound Estimate of *In Vivo* Adverse Effect Levels and in Risk-Based Prioritization

Katie Paul Friedman <sup>1,\*,2</sup>, Matthew Gagne, <sup>3</sup> Lit-Hsin Loo, <sup>4</sup> Panagiotis Karamertzanis, <sup>5</sup> Tatiana Netzeva, <sup>6</sup> Tomasz Sobanski, <sup>7</sup> Jill A. Franzosa, <sup>8</sup> Ann M. Richard, <sup>9</sup> Ryan R. Lougee, <sup>10,11</sup> Andrea Gissi, <sup>12</sup> Jia-Ying Joey Lee, <sup>13</sup> Michelle Angrish, <sup>14</sup> Jean Lou Dorne, <sup>15,16</sup> Steven Foster, <sup>17</sup> Kathleen Raffaele, <sup>18</sup> Tina Bahadori, <sup>19</sup> Maureen R. Gwinn, <sup>20</sup> Jason Lambert, <sup>21</sup> Maurice Whelan, <sup>22</sup> Mike Rasenberg, <sup>23</sup> Tara Barton-Maclaren, <sup>24</sup> and Russell S. Thomas <sup>25,\*</sup>

<sup>1</sup>National Center for Computational Toxicology, Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, NC, 27711; <sup>2</sup>Healthy Environments and Consumer Safety Branch, Health Canada, Government of Canada, Ottawa, Ontario, Canada, K1A0K9; <sup>3</sup>Innovations in Food and Chemical Safety Programme and Bioinformatics Institute, Agency for Science, Technology and Research, Singapore, 138671, Singapore; <sup>4</sup>Computational Assessment Unit, European Chemicals Agency, European Chemicals Agency Annankatu 18, P.O. Box 400, FI-00121 Helsinki, Uusimaa, Finland; <sup>5</sup>National Health and Environmental Effects Research Laboratory, Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, NC, 27711; <sup>6</sup>Oak Ridge Institute for Science and Education, U.S. Department of Energy, Oak Ridge, TN 37831, USA; <sup>7</sup>National Center for Environmental Assessment, Office of Research and Development, US Environmental Protection Agency, Washington, DC, 20004 and Research Triangle Park, NC 27711; <sup>8</sup>Scientific Committee and Emerging Risks Unit Department of Risk Assessment and Scientific Assistance, Via Carlo Magno 1A, 43126 Parma, Italy; <sup>9</sup>Office of Land and Emergency Management, U.S. Environmental Protection Agency, Washington, DC, 20004; and <sup>10</sup>European Commission, Joint Research Centre (JRC), Via Enrico Fermi, 2749, I-21027 Ispra, Italy

\*To whom correspondence should be addressed at 108 T.W. Alexander Drive, Mail Drop D143-03, Research Triangle Park, NC 27711. Fax: (919) 541-1194. E-mail: paul.friedman.jard@epa.gov

Disclaimer: The United States Environmental Protection Agency (U.S. EPA) through its Office of Research and Development has subjected this article to Agency administrative review and approved it for publication. Mention of trade names or commercial products does not constitute endorsement for use. The views expressed in this article are those of the authors and do not necessarily represent the views or policies of A\*STAR, U.S. EPA, EFSA, Health Canada, or the JRC.

- Retrospective Case Study Examining the Utility of *In Vitro* Bioactivity as a Conservative Point of Departure

- Leads: US EPA and Health Canada
- Partners: EChA, EFSA, A\*STAR



**APCRA**  
ACCELERATING THE PACE OF  
CHEMICAL RISK ASSESSMENT

- Linking Exposure to Toxicology Using Lead as Case Study

- Lead: US EPA
- Partners: EFSA, CalEPA, INERIS



[Toxicol Sci.](https://doi.org/10.1093/toxsci/kfz201) 2019 doi: 10.1093/toxsci/kfz201

This space reserved  
for video image.

# Benefits of International Collaborations

- Platforms for innovation and idea exchange between a broader range of stakeholders
- Lead discussions on when there is sufficient knowledge and confidence to bring NAMs into particular regulatory contexts
- Continue to develop new collaborative case studies to address gaps in common scientific and regulatory needs
- Sharing resources and lessons learned
- Increase regulatory confidence in NAMs



This space reserved  
for video image.

# Continued Goals

- Continued increased understanding of NAMs
- Building scientific confidence
- Expand translation of NAMs
- Increased implementation in risk assessment and regulatory decisions
- Create a potential pipeline from sharing information to developing harmonized approaches, results of which may be covered under mutual acceptance of data under OECD



This space reserved  
for video image.

# Acknowledgements

*Thanks to the following for assistance in preparation of this presentation:*

*Giorgia Pallocca, EUToxRisk*

*Patience Browne, OECD*



This space reserved  
for video image.